1. Pink Sheet
  2. >>R&D

Gottlieb Takes Aim At CROs’ ‘Outdated Processes’ In Push For Clinical Trial Digitization

 
• By Sue Sutter

Better use of digital tools to capture – and audit – data can help lower developmental costs, US FDA commissioner says, urging a move away from manual processes ‘perpetuated by entrenched players like contract research organizations that profit off the old ways of doing things.’

An archer with bow takes aim at target

US FDA Commissioner Scott Gottlieb is taking aim at contract research organizations, and what he calls their outdated practices, in pushing to bring drug development and regulation fully into the digital age.

In prepared remarks delivered at a Reagan-Udall Foundation meeting on expanded access Nov. 19, Gottlieb talked about opportunities to improve...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By Vibha Sharma

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.